Aims Variants of renin-angiotensin system genes are shown to be associated with cardiovascular pathology. The association between renin-angiotensin system genes and left ventricular mass was investigated in a population-based case-control study.
Introduction
Left ventricular hypertrophy is an independent predictor of cardiovascular morbidity and mortality [1] [2] [3] . The main population-level determinants of left ventricular mass are race [4, 5] , age, gender, obesity and blood pressure [6, 7] . Other determinants are salt intake [8] , alcohol consumption [9] , insulin sensitivity [10, 11] and genetic factors [12, 13] . The renin-angiotensin system plays an important role in the regulation of blood pressure, electrolyte balance and vascular tone. The angiotensin-converting enzyme (ACE) is a membrane-bound enzyme which is located in vascular endothelial cells and is widely distributed in the body, converts angiotensin I to active angiotensin II and inactivates a vasodilator and natriuretic peptide bradykinin. Angiotensin II, the end product of the renin-angiotensin system is a potent vasopressor peptide, which also has cell-growth promoting or modulating features [14, 15] . In addition to the circulating renin-angiotensin system, angiotensin II has a local paracrine and autocrine action [16] . Local synthesis of angiotensin I and II is utilized in the heart muscle [17] , and ACE is increased in level and activity in hypertrophied heart muscle [18] . The ACE gene located in the non-coding region of the gene (intron 16) has two allelic forms, depending on the presence (insertion, I) or absence (deletion, D) of a 287 base-pair DNA sequence. The D allele is shown to be associated with different cardiovascular pathologies [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] , although contradictory results have been reported [30] [31] [32] [33] [34] . Both circulating and cardiac ACE levels are highest in the DD genotype [35] [36] [37] . The angiotensinogen gene has been found to have several variants [38] . The methionine<threonine (M/T) variant at position 235 has been shown to be associated with hypertension [38] [39] [40] [41] , blood pressure level [38, 42] and plasma angiotensin level [38] . Animal studies have shown that the angiotensinogen concentration in cardiac tissue is low compared to the plasma concentration, although cardiac angiotensinogen expression is enhanced in heart failure [43] . Previous studies have reported contradictory results as regards the association between ACE I/D polymorphism and left ventricular hypertrophy or left ventricular mass [22, 23, 31, 34, 44, 45] and there are only a few observations on the association between left ventricular mass and the variants of the angiotensinogen gene [46, 47] . Although polymorphisms of single genes seem to have no affect on left ventricular mass, the interactions of the gene products within a given biochemical and physiological pathway (renin-angiotensin system) may have synergistic affects on left ventricular mass. We therefore decided to investigate the association between the genetic variants of the renin-angiotensin system (i.e. the angiotensinogen and ACE gene) and left ventricular mass determined by echocardiography in a middle-aged population-based cohort randomly selected from an ethnically homogeneous population.
Methods

Subjects
OPERA (Oulu Project Elucidating Risk of Atherosclerosis) is a population-based, epidemiological study addressing the risk factors and disease end-points of atherosclerotic cardiovascular diseases. The whole OPERA cohort was used as a study population here. The selection of the study subjects has been described elsewhere [48] . Briefly, the hypertensive cohort (cases) consisted of 600 subjects (300 men and 300 women, aged 40-59 years at the time of selection) from the town of Oulu. They were randomly selected from the national register by the Social Insurance Institution if there were reimbursement costs for anti-hypertensive medication. For each hypertensive subject, an age-and sex-matched control was randomly selected from the national health register (including all inhabitants), excluding subjects with the right to reimbursement for hypertension medication.
The overall participation rate of the hypertensives was 86·5% (261 men, 258 women) and that of the controls 87·7% (259 men and 267 women). All the participants visited the research unit between January 1991 and March 1993 for laboratory tests, a physical examination and an interview. Echocardiography was performed on separate visits about 6-12 months later. Of the 1011 subjects who underwent echocardiography, a total of 155 (15·3%) were excluded for the following reasons: poor echocardiographic image quality (66 subjects, 40 hypertensives and 26 controls), significant echocardiographic pathology (mostly significant valve lesions) (29 subjects, 17 hypertensives and 12 controls), missing DNA polymorphism data (13 subjects, 11 hypertensives and 2 controls) and finally, 47 control subjects (20 men and 27 women) were excluded due to ongoing cardiovascular medication. Altogether 856 subjects were included in the study population.
Alcohol consumption was determined in an extensive interview concerning the amount of beer, wine and strong alcoholic beverages consumed. In a questionnaire, all the participants were asked in detail about their smoking habits, physical activity, use of medications and past medical history. Alcohol consumption was calculated as grams of absolute alcohol per week and smoking as the number of cigarettes smoked per day. Body mass index was calculated by dividing weight (kg) with the square of height (m 2 ). Physical activity was determined through an interview and scored in five categories, where 5=highly active and 1=sedentary [49] .
Blood pressure recording
Blood pressure was measured in a sitting position from the right arm with an oscillometric device (Dinamap model 18465X, Criticon Ltd., Ascot, U.K.) after an overnight fast and after 10-15 min rest. Three measurements were made at 1 min intervals. The means of the last two measurements were used for the analyses.
DNA analyses
Genomic DNA was isolated from EDTA blood by using a salting-out method according to Miller et al. [50] . The I/D polymorphism of the ACE gene was detected by using polymerase chain reaction. The primers were selected according to Rigat et al. [51] . Amplification reactions were performed in a final volume of 50 l containing 67 mmol . (HyTest) . DNA was amplified in a thermal cycler with 1 min denaturation at 94 C, 1 min annealing at 65 C and 2 min extension at 72 C for 30 cycles. In the last cycle, the extension step was carried out for 10 min. Polymerase chain reaction products were separated on a 2% agarose gel containing ethidium bromide and visualized in ultraviolet light. The lengths of the fragments separated were 478 bp and 191 bp, corresponding to the insertion allele (I) and the deletion allele (D), respectively. Since previous reports [52, 53] have suggested that the D allele is preferentially amplified, the polymerase chain reactions were reanalysed in two different ways. The addition of dimethylsulphoxide (DMSO) to the reaction mixture described above, or the use of the insertion-specific primer [53] confirmed the results of the original polymerase chain reactions.
The M235T variant of the angiotensinogen gene was detected using the polymerase chain reaction detection method. The primers were selected according to Russ et al. [54] . The amplification reactions were performed in a final volume of 25 l, as described above, except that the initial denaturation was for 3 min at 90 C, with 10 cycles at 94 C for 1 min, at 68 C for 1 min, at 72 C for 1 min, and 30 cycles at 90 C for 30 s, at 68 C for 1 min and at 72 C for 30 s, followed by a final extension of 72 C for 10 min. Three microlitres of unpurified polymerase chain reaction product was diluted to 10 l in the recommended restriction buffer containing 5 U of the Tth 111 I enzyme (Pharmacia) and digested at 65 C under mineral oil for over 3 h. The digested polymerase chain reaction products were separated on 3% agarose gel containing ethidium bromide and visualized in ultraviolet light. The lengths of the separated fragments were 165 bp, corresponding to the M235 allele (M), and 141 bp, corresponding to the digested T235 allele (T) [54] .
Echocardiographic methods
All echocardiographic examinations were performed with the Hewlett-Packard Sonos 500 (Hewlett-Packard Company, Massachusetts, U.S.A.) by one trained cardiologist blinded to the grouping of the study subjects. The left ventricular internal diameters and wall thickness were measured from M-mode recordings under 2-D guidance according to the recommendations of the American Society of Echocardiography [55] . The left ventricular mass was calculated from the ASE measurements according to the corrected equation [56] :
where IVS is the end-diastolic interventricular septum thickness, LVID is the end-diastolic left ventricular internal dimension and PWT is the end-diastolic posterior wall thickness. The left ventricular mass index was calculated by dividing left ventricular mass (g) by body surface area (m 2 ). Body surface area was determined by the Dubois equation [57] :
The left ventricular hypertrophy cut-off points were >134 g . m 2 in men and >110 g . m 2 in women [58] . Relative left ventricular wall thickness was calculated as follows:
Statistical analyses
Allele frequencies were estimated with the gene counting method. A chi-square-test was used to assess the fit of the observed allele frequencies to the agreement of the Hardy-Weinberg equilibrium and the difference in genotype distributions between the control groups and the hypertensive groups. When the number of subjects in one or more cells of the contingency table was low (five or less), Fisher's exact test was used.
The continuous variables were expressed as means SD or SE according to the genotypes (II, ID, DD and MM, MT, TT). The unpaired t-test was used when comparing the means of two groups. The differences between variables in the different genotype groups were compared with the analysis of variance (ANOVA). Due to the skewed distribution, logarithmic transformation was used for alcohol consumption and the plasma levels of insulin. A two-way ANOVA (3 3 factorial design) was used for the potential synergistic effect of the ACE gene and the angiotensinogen gene on left ventricular mass. Bonferroni's method was used for multiple comparisons between the genotype classes. Analysis of covariance was used to adjust the echocardiographic variables for the effect of age, body mass index, systolic blood pressure, fasting insulin, physical activity and gender, when appropriate. Body mass index was excluded from the covariates when left ventricular mass index values were adjusted. To assess the relative risk of different factors for left ventricular hypertrophy, multiple logistic regression analysis was used. The regressor variables in the model were age, systolic blood pressure, fasting insulin, physical activity and genotype as a dummy variable [genotypes II (MM) and ID (MT) combined vs DD (TT), and genotype ID (MT) and DD (TT) combined vs II (MM)]. Regressor variables (except the genotype) were selected according the correlation analysis, where left ventricular mass index was significantly correlated with blood pressure and body mass index in men and with blood pressure, body mass index, fasting insulin level, physical activity and age in women. The regression analysis was made separately for men and women.
The Statistical Analysis System (SAS, version 6.08, SAS Institute Inc., Cary; North Carolina, U.S.A.) was used in all the statistical analyses.
Results
The genotype distribution and the main characteristics of the study subjects by the ACE and angiotensinogen genotypes are shown in Tables 1 and 2 . The frequency of the D allele was 55·3% in hypertensives and 54·5% in control subjects, and the frequencies of the T allele were 49·7% and 46·0%, respectively. The genotype distributions both in all subjects and in males and females separately were in agreement with the Hardy-Weinberg equilibrium. The number of control women homozygous for the D allele of the ACE gene was considerably lower than in control men (23·6% vs 33·5%). Small differences in the main characteristics were seen when genders were analysed separately. Hypertensive women with the TT genotype were slightly younger (P=0·01) and had lower blood pressure (P=0·002) than women with the MM and MT genotypes. Further, alcohol consumption in hypertensive men with the TT genotype was lower (P=0·03) than in other genotypes. Control men with the MM genotype had slightly lower body mass index (P=0·03) than other genotypes. Table 3 shows the values of left ventricular mass, left ventricular mass index and other echocardiographic variables in the hypertensive and control subjects by genotypes. There were no differences in left ventricular mass or left ventricular mass index values between the different genotypes among either the hypertensive or the control subjects, irrespective of gender. Furthermore, no significant association was seen between the genotypes and left ventricular mass or left ventricular mass index values in the subgroups of normotensive (systolic blood pressure <160 mmHg and diastolic blood pressure <95 mmHg) or physically active (physical activity score d3) control subjects (data not shown). Also, the values of the end-diastolic left ventricular internal dimension and relative wall thickness were very similar in different genotypes (Table 3) . All values (except the number of subjects) are means (SD). BMI=body mass index; SBP=systolic blood pressure. *P<0·05 (ANOVA). Table 4 shows the genotype distributions of the ACE and angiotensinogen genes by left ventricular hypertrophy. No significant difference in genotype distribution or allele frequencies were seen between those with or without left ventricular hypertrophy when genders were analysed-pooled. In the control women, the D allele was associated with left ventricular hypertrophy, the difference in the frequency of the D allele between those with and without left ventricular hypertrophy being 15% (0·63 vs 0·48, chi-square=7·05, P=0·04). However, in women with left ventricular hypertrophy (n=34) only five had the II genotype, 15, ID and 14, DD. This allele difference was even more pronounced in normotensive control women (0·73 vs 0·48, 
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Hypertensives ( chi-square=10·4, P=0·01) and in physically active control women (0·69 vs 0·47, chi-square=9·39, P=0·01). However, there were few women with left ventricular hypertrophy and the II genotype in these subgroups (one and two, respectively). The odds ratios with confidence intervals obtained by multiple logistic regression analysis are shown in Table 5 . Control women with the DD genotype had a significantly increased risk of left ventricular hypertrophy. In addition, this was observed when the left ventricular hypertrophy cut-off point was >100 g . m 2 [odds ratio 1·98 (1·01; 3·88)]. When left ventricular hypertrophy was determined by the relative wall thickness value >0·45, no significant odds ratios were observed in any group.
No significant interaction between the ACE and angiotensinogen genotypes was seen on left ventricular mass in either all control/hypertensive subjects or the genders separately (two-way ANOVA with a 3 3 factorial design) (data not shown).
Discussion
The association between the variation in two reninangiotensin system genes and left ventricular mass were investigated in a random well-characterized cohort of middle-aged hypertensive subjects and population-based control subjects. The study subjects were drawn from an ethnically relatively homogeneous population living in the town of Oulu, Finland. No association between the genotypes of the ACE or angiotensinogen gene and left ventricular mass was observed, nor was any significant joint effect of these genes seen on left ventricular mass. Similarly, genotypes had no significant effect on left ventricular wall thickness or end-diastolic diameter. In the control women, the D allele of the ACE gene may increase the risk of left ventricular hypertrophy. The present study cohort was randomly drawn from a geographically limited and ethnically homogeneous population, which is an ideal approach for genetic epidemiological studies [59] , and due to the relatively high participation rate, the control cohort may represent the general middle-aged Caucasian population.
Bearing in mind that the cut-off points of left ventricular hypertrophy used in this study are based on adult healthy population and correspond to the 97th percentile of normality [58] , the prevalence of left ventricular hypertrophy (19%) in the control subjects of the present study is relatively high. Although the reasons for this discrepancy are not clear, it does not adversely affect the interpretation of this study. It is emphasized, that the samples of Devereux et al. were younger (mean age 44 and 33 years) and had much lower blood pressure (mean 120/76 and 119/73 mmHg) than the control subjects here. In fact, 35% of the control men and 19% of the control women had systolic blood pressure d160 or diastolic blood pressure d95 mmHg. Obviously the true prevalence of left ventricular hypertrophy in the present population is significantly higher than in the reference cohorts of Devereux et al. The prevalence of echocardiographic left ventricular hypertrophy in the Framingham Study population was 16% in men and 19% in women, prevalences increasing clearly with age [7] . Previously, the results concerning the association between left ventricular mass or left ventricular hypertrophy and ACE I/D polymorphism have been contradictory. In one large study, the DD genotype was associated with left ventricular hypertrophy in middleaged men, the association being most pronounced in normotensive subjects [22] . In that particular study, however, left ventricular mass was not studied and left ventricular hypertrophy was determined by different electrocardiographic criteria. It is well known that echocardiography is more sensitive than electrocardiography in estimating left ventricular mass [2] and left ventricular hypertrophy [60] . In the present study, standard electrocardiography was also performed on all subjects. Left ventricular hypertrophy determined by the tall R wave criterion of the Minnesota code (3·1) [61] was seen in 8·1% of control men and in 3·4% of control women. There was no association between left ventricular hypertrophy determined in this way and the ACE or angiotensinogen genotypes in any of the subgroups (in all control women the ACE genotype was linked to left ventricular hypertrophy with a chi-square value of 0·83 and a P value of 0·7). In studies with a positive association between left ventricular mass and the D allele of ACE polymorphism, the study population has consisted of hypertensive subjects [44, 45] or a subgroup (142 out of 450) of the primary study population based on hospital patients [23] . Lindpaintner et al. observed neither an association, nor a genetic linkage between ACE I/D polymorphism and left ventricular hypertrophy or left ventricular mass in a study based on the Framingham Heart Study population [34] . The present results, which show no association between left ventricular mass and the ACE polymorphism, are in agreement with the results of Lindpaintner et al. and some other studies [31, 62] . There are several factors which may explain why an association seen in one population will not be replicated in others. In genetic epidemiology, the genetic background of study populations and the selection methods of study subjects are critical points and differences in these factors may explain, at least in part, the controversial results in the literature.
In the present study, the D allele was significantly more common in the control women with left ventricular hypertrophy than in those without it. This phenomenon was equally apparent in all women, in normotensive women and in physically active women and it was also seen when a less stringent cut-off point for left ventricular hypertrophy was applied. A previous study [22] suggested that the frequency of the D allele among subjects with left ventricular hypertrophy would be approximately 60% and the expected prevalence in control subjects would not exceed 54%. If we assume that a difference of this magnitude (odds ratio 1·76) would strongly support the notion that the D allele is a significant genetic risk factor, and with a two-sided alpha error of 0·05, the sample size should be approximately 1080 in each group to limit the beta error to 0·20 (i.e. the power of the study would be 80%). When the number of subjects in each group is about 100 (as is the case in the present study when the genders are analysed separately), and with an alpha error of 0·05 and a beta error of 0·20, an allele difference of 19% would be the minimum value to support the genetic risk factor of the D allele for left ventricular hypertrophy. An allele difference of this magnitude was achieved only in subgroups of normotensive and physically active control women and because these associations were based on a small number of subjects with left ventricular hypertrophy, they should be interpreted with caution. All in all, the association seen in control women may be due to chance observations and might be linked to the extraordinarily low number of DD subjects in the control women (23·6% vs 33·5% in control men) and low frequency of the D allele (0·505 vs 0·583 in control men). In other population-based studies with a high number of participants, the proportion of DD subjects has been clearly higher (28-40%) than in the female control group of the present study. Furthermore, the lack of association between left ventricular mass and ACE polymorphism argues against a true association.
So far, there are only a few observations regarding the association between the angiotensinogen gene variants and left ventricular mass or left ventricular hypertrophy [46, 47] . In a newly published abstract paper, a positive association was observed in a small group of young normotensive subjects [47] . Our study revealed no association, although some tendency towards higher left ventricular mass values was observed in the control men with the TT genotype. Since the T235 allele of the angiotensinogen gene is a maker of a higher plasma angiotensinogen concentration [38] and may be linked to higher blood pressure [38, 42] , the higher left ventricular mass in the TT subjects (men) could be explained by the activation of the circulating (or local) renin-angiotensin system and/or by a higher blood pressure level.
In many studies, the D allele has been shown to be associated with different cardiovascular pathologies, such as myocardial infarction (particularly in subjects without conventional risk factors) [19, 21, [24] [25] [26] , dilated and ischaemic cardiomyopathy [20] , restenosis after coronary angioplasty [27] and carotid artery atherosclerosis [28, 29] . Because many of these conditions can be considered a result of trophic cell growth, it would be plausible to assume a positive association between the variants of the ACE gene and left ventricular mass. On the other hand, it must be emphasized that ACE polymorphism is not linked to the plasma angiotensin II level in spite of the association between plasma ACE activity and ACE polymorphism [35, 36] . It is possible that a prospective study, rather than the cross-sectional design used here or a considerably larger study population would be necessary to document or reject the suggested positive association between ACE polymorphism and left ventricular mass in a general population.
We conclude that no significant association between the variants of renin-angiotensin system genes and left ventricular mass or left ventricular hypertrophy was seen in this representative population-based cohort of hypertensive and control subjects. 
